Driving Branded Generics Market Growth in 2025: The Role of Rising Prevalence Of Chronic Diseases Propelling Growth In Branded Generics Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Branded Generics Market Size By 2025?
The market size for branded generics has seen significant growth over the past few years. It is projected to increase from $363.49 billion in 2024 to $397.19 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. Factors such as cost savings and affordability, expiration of patents, market growth and accessibility, government policies, and healthcare reforms have contributed to the growth seen in the historical period.

How Big Is the Branded Generics Market Size Expected to Grow by 2029?
We anticipate swift expansion in the branded generics market in the upcoming years. It's projected to reach a value of $601.4 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.9%. The increase in this time frame can be linked to a rising demand for generic biologics, an uptick in chronic disease cases, growth in emerging markets, and a heightened focus on biosimilars. Looking ahead, strategic cooperative ventures, advancements in technology, a heightened focus on chronic diseases, market consolidation, and a patient-focused approach will be the primary trends shaping the forecast period.

View the full report here:
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Key Market Drivers Powering Branded Generics Market Expansion and Growth?
The rise in chronic diseases is anticipated to propel the growth of the branded generics market. Chronic illnesses are enduring conditions that, although they can't be cured, can be managed and treated effectively. The increase in chronic diseases can be associated with various factors such as increased consumption of tobacco, poor dietary habits, lack of physical exercise, overuse of alcohol, etc. Global customers are showing a preference for branded-generic drugs for the treatment of chronic diseases as they are cost-efficient compared to traditional medications. For instance, as per the World Health Organization (WHO) 2022 Highlights in September 2022, a health organization based in Switzerland, 41 million recorded deaths - 74% of all global deaths were attributed to noncommunicable diseases (NCDs) or chronic diseases annually. Therefore, the escalating prevalence of chronic diseases is predicted to enhance the demand for branded generics in the forthcoming period.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Branded Generics Market?
Collaborations and strategic alliances have emerged as a crucial trend in the branded generics sector. Firms in this field engage in partnerships with suitable companies to pool resources and extend their reach into new markets. Take for instance, Biocon Ltd., an Indian pharmaceutical company initiated a partnership with Tabuk Pharmaceuticals in September 2024. Biocon's role is centered on developing and manufacturing GLP-1 products that offer top-notch biopharmaceuticals targeted at diabetes treatment. The marketing authorization rights have been given to Tabuk, a pharmaceutical company based in Saudi Arabia. They will oversee the registration, import, and promotion of these products primarily in the Middle East, notably in Saudi Arabia. The alliance also projects future expansion to include more GLP products above the initial offerings, widening the spectrum of diabetes treatment options. With a goal to offer enhanced health solutions improving patient well-being in Saudi Arabia and nearby regions, this partnership aligns with both companies' dedication to enhancing healthcare accessibility. Tabuk is renowned for marketing both branded and generic pharmaceutical products.

What Are the Emerging Segments in the Branded Generics Market?
The branded generics market covered in this report is segmented -

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Who Are the Global Leaders in the Branded Generics Market?
Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Which are the Top Profitable Regional Markets for the Branded Generics Industry?
North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.